EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tuberculosis in patients with cancer: is screening for latent TB infection necessary?

Hannah Ward, Olivia Lucey, Veronica White, John Gribben, Jonathan Lambourne

Clinical Infection in Practice · 2026-08 · 31 · 100713

DOI: 10.1016/j.clinpr.2026.100713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infection in Practice, 2026-08. Verfasst von Hannah Ward und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB) in patients with haematological and solid malignancies is uncommon, and data on the impact of screening cancer patients for latent TB infection (LTBI) is limited. Recent European guidelines describing potential screening approaches prompted a review of TB cases at Barts Cancer Centre, a large specialist oncology centre, to identify the best screening strategy.

Methods

Positive Mycobacterium tuberculosis cultures and/or polymerase chain reaction (PCR) results from August 2017 to July 2023 were analysed, and electronic health records were reviewed to identify concomitant cancer diagnoses. Demographics, TB risk factors, clinical presentation, cancer treatment and outcomes were assessed.

Results

Sixteen patients with culture-confirmed TB were identified; seven pulmonary cases (of which two also had intrathoracic lymph node (LN) disease), four cases confined to intrathoracic lymph nodes, three disseminated, one pleural and one retropharyngeal with spinal disease. Five (31.3%) had undergone cancer chemotherapy reported to increase TB risk. None had a previous history of TB infection. TB contact was documented clearly in 12 cases of which three (18.8%), extra-pulmonary and disseminated cases, reported historical contact with a TB-infected individual. The median interval between cancer and TB diagnoses was 17 months. Among haematooncology patients; 5/7 (71.4%) developed TB within two months of starting cancer chemotherapy and 5/7 (71.4%) presented with persistent fever. Comparatively, 5/9 (55.6%) solid-oncology cases were incidentally identified through imaging.

Conclusion

This retrospective cohort study highlights the rarity of TB infection among cancer patients and identifies the challenges of risk-based screening. No universal risk factor was identified, while some patients lacked any apparent risk factors. These findings advocate for a pre-emptive approach to TB diagnosis, promoting early consideration of investigation of active TB following cancer chemotherapy initiation, particularly in patients with persistent fever and TB risk factors.

Zitieren

APA

Ward, H., Lucey, O., White, V., Gribben, J., & Lambourne, J. (2026). Tuberculosis in patients with cancer: is screening for latent TB infection necessary?. Clinical Infection in Practice, 31, 100713. https://doi.org/10.1016/j.clinpr.2026.100713

Vancouver

Ward H, Lucey O, White V, Gribben J, Lambourne J. Tuberculosis in patients with cancer: is screening for latent TB infection necessary?. Clinical Infection in Practice. 2026;31:100713. doi:10.1016/j.clinpr.2026.100713

BibTeX
@article{Ward2026,
  author = {Ward, Hannah and Lucey, Olivia and White, Veronica and Gribben, John and Lambourne, Jonathan},
  title = {Tuberculosis in patients with cancer: is screening for latent TB infection necessary?},
  journal = {Clinical Infection in Practice},
  year = {2026},
  volume = {31},
  pages = {100713},
  doi = {10.1016/j.clinpr.2026.100713}
}
Kostenlos starten →